Terms: = Liver cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Treatment
82 results:
1. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract] [Full Text] [Related]
2. Knowledge, attitude, and practice toward weight management among diabetic patients in Qidong City, Jiangsu Province.
Li X; Shi Y; Wei D; Gong Y; Yan X; Cai S
BMC Public Health; 2024 Mar; 24(1):922. PubMed ID: 38553699
[TBL] [Abstract] [Full Text] [Related]
3. Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells.
Jantaravinid J; Tirawanchai N; Ampawong S; Kengkoom K; Somkasetrin A; Nakhonsri V; Aramwit P
Sci Rep; 2024 Mar; 14(1):5455. PubMed ID: 38443583
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA cebpa-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.
Cai Y; Lyu T; Li H; Liu C; Xie K; Xu L; Li W; Liu H; Zhu J; Lyu Y; Feng X; Lan T; Yang J; Wu H
J Exp Clin Cancer Res; 2022 Dec; 41(1):335. PubMed ID: 36471363
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic network biomarker analysis and system pharmacology methods to explore the therapeutic effects and targets of Xiaoyaosan against liver cirrhosis.
Lu Y; Li M; Zhou Q; Fang D; Wu R; Li Q; Chen L; Su S
J Ethnopharmacol; 2022 Aug; 294():115324. PubMed ID: 35489663
[TBL] [Abstract] [Full Text] [Related]
6. Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.
Kefayat A; Hosseini M; Ghahremani F; Jolfaie NA; Rafienia M
J Nanobiotechnology; 2022 Mar; 20(1):169. PubMed ID: 35361226
[TBL] [Abstract] [Full Text] [Related]
7. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract] [Full Text] [Related]
8. Scutebarbatine A induces cytotoxicity in hepatocellular carcinoma via activation of the MAPK and ER stress signaling pathways.
Feng PP; Qi YK; Li N; Fei HR
J Biochem Mol Toxicol; 2021 May; 35(5):e22731. PubMed ID: 33512038
[TBL] [Abstract] [Full Text] [Related]
9. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D;
BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326
[TBL] [Abstract] [Full Text] [Related]
10. Diphlorethohydroxycarmalol Attenuates Palmitate-Induced Hepatic Lipogenesis and Inflammation.
Cha SH; Hwang Y; Heo SJ; Jun HS
Mar Drugs; 2020 Sep; 18(9):. PubMed ID: 32962167
[TBL] [Abstract] [Full Text] [Related]
11. MTL-cebpa, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced liver cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
[TBL] [Abstract] [Full Text] [Related]
12. No-Touch Multi-bipolar Radiofrequency Ablation for the treatment of Subcapsular Hepatocellular Carcinoma ≤ 5 cm Not Puncturable via the Non-tumorous liver Parenchyma.
Petit A; Hocquelet A; N'kontchou G; Varin E; Sellier N; Seror O; Sutter O
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):273-283. PubMed ID: 31673728
[TBL] [Abstract] [Full Text] [Related]
13. Dual effects of gossypol on human hepatocellular carcinoma via endoplasmic reticulum stress and autophagy.
Zhang G; Wang Z; Chen W; Cao Y; Wu J; Qiang G; Ji A; Wu J; Jiang C
Int J Biochem Cell Biol; 2019 Aug; 113():48-57. PubMed ID: 31128260
[TBL] [Abstract] [Full Text] [Related]
14. Developing small activating RNA as a therapeutic: current challenges and promises.
Kwok A; Raulf N; Habib N
Ther Deliv; 2019 Mar; 10(3):151-164. PubMed ID: 30909853
[TBL] [Abstract] [Full Text] [Related]
15. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population.
Zarour LR; Billingsley KG; Walker BS; Enestvedt CK; Orloff SL; Maynard E; Mayo SC
Am J Surg; 2019 May; 217(5):899-905. PubMed ID: 30819401
[TBL] [Abstract] [Full Text] [Related]
16. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells.
Rodríguez-Hernández MA; González R; de la Rosa ÁJ; Gallego P; Ordóñez R; Navarro-Villarán E; Contreras L; Rodríguez-Arribas M; González-Gallego J; Álamo-Martínez JM; Marín-Gómez LM; Del Campo JA; Quiles JL; Fuentes JM; de la Cruz J; Mauriz JL; Padillo FJ; Muntané J
J Cell Physiol; 2018 Jan; 234(1):692-708. PubMed ID: 30132846
[TBL] [Abstract] [Full Text] [Related]
17. Development of MTL-cebpa: Small Activating RNA Drug for Hepatocellular Carcinoma.
Setten RL; Lightfoot HL; Habib NA; Rossi JJ
Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
[TBL] [Abstract] [Full Text] [Related]
18. Gene activation of cebpa using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
[TBL] [Abstract] [Full Text] [Related]
19. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract] [Full Text] [Related]
20. Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress.
Lv SX; Qiao X
Biochem Biophys Res Commun; 2018 Feb; 496(4):1047-1054. PubMed ID: 29355527
[TBL] [Abstract] [Full Text] [Related]
[Next]
